EDUCATION

BA Biochemistry, Cum Laude, Harvard '84;
MD, New York University '88;
Residency Ob/Gyn, University of Pennsylvania '92;
Fellowship,Gynecologic Oncology, UC Irvine, '96.

CURRENT POSITION

Assistant Professor, Department of Ob/Gyn, Division of Gynecologic Oncology, UC Irvine.

QUALIFICATIONS

National board certification, Ob/Gyn and Gynecologic Oncology
Service to national organizations (SGO, SWOG, GOG)
Reviewer, 9 scientific journals
Investigator, several national clinical trials
Director of Phase II Ovarian Cancer Trials, GOG
Chair, IRB
NIH grant recipient

CLINICAL INTERESTS

EW #828 is a a board-certified obstetrician-gynecologist, is one of the most "up and coming" gynecologic oncologists in the United States. He has a strong and growing reputation in academic gynecologic oncology, as well as a strong track record of achievement in both the clinical and basic sciences. Hisexpertise and clinical interests are in the areas of Women's Health, gynecologic cancers, prevention, and screening. Heis an expert in performing radical pelvic surgery, including ovarian cancer surgery, gastrointestinal and urologic procedures.

RESEARCH INTERESTS

EW #828's research interests are principally in the field of ovarian cancer biology and therapeutics. This work is being conducted in the Division of Gynecologic Oncology, some through collaboration with other principal investigators at UCI and in national cooperative groups.

Hisexpertise in the medical informatics, database design and management, and statistical methods has benefited major projects within the Division of Gynecologic Oncology. For example, he established and coordinated a clinical and research database system, which is now networked across four medical campuses. In 2003, he was appointed as Chair of the Informatics Committee of the SGO.

SELECTED PUBLICATIONS

Single-visit program for cervical cancer prevention in a high-risk population. Obstet Gynecol 86(4):491-498, 1995

Human papillomavirus type 18: Association with poor prognosis in early stage cervical cancer. J. Natl Cancer Inst 88(19):1361-1368, 1996.

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 72:148-153, 1999

Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Nat Acad Sci USA 98: 1176-1181, 2001.

Fertility Sparing Treatment for In Situ and Early Invasive Adenocarcinoma of the Cervix. Obstetrics & Gynecology. 98 (5) 726-731, Nov. 2001.

Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg 193 (6): 626-632, Dec. 2001.

Phase III trial of carboplatin and paclitaxel compared to cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J. Clin Oncol 21: (17)3194-3200, Jul. 2003.

In vitro chemotherapeutic drug resistance and biomarker profiles are unique for histologic cell types of epithelial ovarian cancer. Gynecol Oncol 92: (1) 160-166, Jan. 2004. (Corresponding Author)